XTX Topco Ltd Acquires New Shares in Arvinas, Inc. (NASDAQ:ARVN)

XTX Topco Ltd bought a new position in Arvinas, Inc. (NASDAQ:ARVN) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 18,401 shares of the company’s stock, valued at approximately $453,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. nVerses Capital LLC acquired a new position in Arvinas in the 3rd quarter worth $39,000. Quest Partners LLC acquired a new position in Arvinas in the 2nd quarter worth $42,000. Amalgamated Bank boosted its stake in Arvinas by 29.6% in the 2nd quarter. Amalgamated Bank now owns 2,223 shares of the company’s stock worth $59,000 after purchasing an additional 508 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Arvinas by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock worth $61,000 after purchasing an additional 440 shares during the period. Finally, Quantbot Technologies LP boosted its stake in Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock worth $108,000 after purchasing an additional 2,601 shares during the period. 95.19% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on ARVN shares. Oppenheimer reduced their target price on shares of Arvinas from $50.00 to $40.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. Cantor Fitzgerald restated an “overweight” rating on shares of Arvinas in a research note on Monday, September 9th. HC Wainwright restated a “buy” rating and set a $87.00 price objective on shares of Arvinas in a research note on Wednesday. Stephens started coverage on shares of Arvinas in a research note on Monday, November 18th. They set an “overweight” rating and a $55.00 price objective for the company. Finally, BTIG Research started coverage on shares of Arvinas in a research note on Tuesday, December 10th. They set a “buy” rating and a $69.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $63.50.

Arvinas Stock Performance

Shares of NASDAQ:ARVN opened at $19.50 on Friday. Arvinas, Inc. has a 52-week low of $18.51 and a 52-week high of $53.08. The company has a market capitalization of $1.34 billion, a P/E ratio of -4.18 and a beta of 1.82. The company has a 50-day simple moving average of $25.52 and a 200 day simple moving average of $26.01.

Arvinas (NASDAQ:ARVN) last issued its earnings results on Wednesday, October 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.20. The firm had revenue of $102.40 million during the quarter, compared to analyst estimates of $60.56 million. The company’s revenue for the quarter was up 196.0% on a year-over-year basis. During the same quarter last year, the business posted ($1.18) earnings per share. As a group, equities analysts forecast that Arvinas, Inc. will post -3.22 earnings per share for the current year.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.